Lessons learned from QT prolongation risk assessment for antibody-drug conjugates in oncology
{{output}}
Antibody-drug conjugates (ADCs) are advanced cancer therapeutics that link monoclonal antibodies to cytotoxic drugs, enhancing targeted delivery to tumors. Since the FDA's first ADC approval in 2000, 14 ADCs have received approval to date (March 2025), unders... ...
